Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Australian hemp company Elixinol Global (EXL) has appointed Oliver Horn as Group CEO effective immediately
  • He will be replacing Stratos Karousos who helped the company become a more streamlined, efficient and focused business
  • Elixinol Global has also announced the appointment of Helen Wiseman to the Board as a Non-Executive Director
  • The company will now focus on its goals of long-term growth and keep the market updated on its progress
  • Elixinol Global has ended the day 6.41 per cent in the red with shares trading for 36.5 cents each

Australian hemp company Elixinol Global (EXL) has appointed Oliver Horn as Group CEO, effective immediately.

He will be replacing Stratos Karousos who helped the company become a more streamlined, efficient and focused business.

Oliver’s extensive global industry experience, leadership credentials, and interest in wellbeing, has made him the primary choice to lead the company.

Previously, he was independent Non-Executive Director of Elixinol Global and his knowledge of the company will be instrumental in guiding it forward.

“It is a privilege to have the opportunity to lead Elixinol’s very capable global team and build on 20+ years of experience in the global hemp industry,” Oliver commented.

“I chose to join Elixinol Global because it has an outstanding reputation for quality, transparency and efficacy. We are in the enviable position of being in a long-term global growth category, with a good brand, and strong market research,” he said.

“My vision is to build a branded global consumer products business, built on a very positive culture which does good for people and the planet,” he added.

Elixinol Global has also announced the appointment of Helen Wiseman to the Board as a Non-Executive Director.

Helen has extensive international experience in the food, pharmaceutical, professional services, manufacturing, natural healthcare, and energy and natural resources sectors.

She has been named as one of the 2014 Australian Financial Review and Westpac 100 Women of Influence.

“These changes put Elixinol Global in a great position to lead within the global CBD and hemp industry. We are very proud to have attracted such exceptional talent to our Board and secured an exceptional leader for the CEO position,” Chairman Paul Benhaim stated.

“We are now looking forward to driving the company towards our goals and will keep the market updated on progress,” he said.

Elixinol Global has ended the day 6.41 per cent in the red with shares trading for 36.5 cents each in a $53.77 million market cap.

EXL by the numbers
More From The Market Herald
Aussie Broadband (ASX:ABB) - Managing Director, Phillip Britt

" Aussie Broadband (ASX:ABB) confirms takeover talks with Over The Wire (ASX:OTW)

In response to an article by The Australian, Aussie Broadband (ABB) has confirmed it is in discussions with Over The Wire (OTW) regarding
Cashrewards (ASX:CRW) - CEO, Bernard Wilson

" ANZ’s (ASZ:ANZ) investment arm to buy Cashrewards (ASX:CRW)

ANZ’s (ANZ) investment arm will aim to buy all of the share in fellow ASX-lister Cashrewards (CRW).
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.